RxDoctor Payments Data

Yvette Neirouz, MD

Internal Medicine · Cincinnati, OHNPI 1508803883

Payments from drug & device makers

$813in general payments, 2019–2025

Across 37 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$248
  • AbbVie$226
  • Astellas Pharma US Inc$161
  • Novo Nordisk$62
  • Ironwood Pharmaceuticals, Inc$37
  • Novartis$24
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$80199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$813 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$109,376
Medicare patients
255
Services billed
1,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide55$68,427
OzempicSemaglutide50$53,713
TrulicityDulaglutide39$50,872
EliquisApixaban62$50,756
JardianceEmpagliflozin32$45,177
RybelsusSemaglutide18$27,879
FarxigaDapagliflozin Propanediol13$17,439
JanuviaSitagliptin Phosphate18$15,925
WegovySemaglutide11$14,542
XareltoRivaroxaban12$12,198
SymbicortBudesonide/Formoterol Fumarate22$8,091
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$6,282
Humalog Kwikpen U-100Insulin Lispro13$6,181
Spiriva RespimatTiotropium Bromide11$5,897
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$4,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$62$96,13379 claims
PfizerEliquis, Paxlovid$15$52,10773 claims
AstraZenecaFarxiga, Symbicort$248$25,53135 claims
AbbVieSynthroid$226$2,67054 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →